Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promega Launches Novel ADCC Reporter Bioassay for Biologics

Published: Thursday, October 11, 2012
Last Updated: Wednesday, October 10, 2012
Bookmark and Share
Frozen, thaw-and-use cells reduce variability compared to PBMCs adn NK cells.

Promega Corporation has announced the introduction of a novel bioluminescent assay for the quantification of Fc effector function of antibody-based molecules in the development and manufacture of biologic drugs.

The assay is ADCC mechanism of action (MOA)-based and features frozen, thaw-and-use effector cells, and optimized reagents and protocol to perform a reporter-based ADCC bioassay in a single day.

The ADCC Reporter Bioassay correlates with classic cytotoxic ADCC assays and is a suitable replacement for these cumbersome and highly variable assays.

Antibody-dependent cell-mediated cytotoxicity (ADCC) is the main MOA of antibodies through which virus-infected or other diseased cells are targeted for destruction by components of the cell mediated immune system, such as natural killer cells.

The ADCC Reporter Bioassay uses an alternative readout at an earlier point in ADCC MOA pathway: the activation of gene transcription through the NFAT (nuclear factor of activated T-cells)
pathway in the effector cell.

In addition, the bioassay uses engineered Jurkat cells stably expressing the FcγRIIIa receptor, V158 (high affinity) variant, and an NFAT response element driving expression of firefly luciferase.

Following extensive in-house studies and a successful alpha trial program, the ADCC Reporter Bioassay is now being adopted by global biologics companies as well as being offered as a service by Charles River Laboratories.

The novel bioassay is linear, accurate, precise and stability indicating. Moreover, the bioassay shows good linear correlation between levels of glycosylation or fucosylation and ADCC activity.

All of these features indicate the assay is suitable for use across biologic drug development programs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promega to Break Ground for New Processing and Manufacturing Facility
Facility will allow for efficiency improvements for processing, packaging, staging and shipping products.
Monday, July 07, 2014
Promega Partners with ATCC to Offer New Cell Systems for Biologics Drug Discovery
Partnership for the cell banking and bioproduction of cells to create a new line of bioluminescence-based drug discovery assays for biologics.
Monday, June 27, 2011
Promega Expansion into Brazil Brings New Convenience and Support for Scientists
Now scientists in life science research, drug discovery and clinical diagnostics have direct access to technical service, fast delivery and the ability to request a quote online in Brazil.
Thursday, April 07, 2011
Scientific News
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
DNA-Based Zika Vaccine Showed Protection From Infection, Brain Damage and Death
The study is the first of its kind to analyze a vaccine in an animal model that is susceptible to the disease, providing information regarding the protective impact of the immune response in susceptible individuals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!